HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Cardiol Therapeutics (NASDAQ:CRDL) and maintained a price target of $9.
June 14, 2024 | 10:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Cardiol Therapeutics and maintained a price target of $9, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $9 by HC Wainwright & Co. suggests strong confidence in Cardiol Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100